Biological Weapons Convention
The Biological Weapons Convention (BWC) — formally the Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on their Destruction — is an international arms control treaty opened for signature on 10 April 1972 and entering into force on 26 March 1975. As of 2024, the BWC has 183 states parties, with a handful of nations remaining outside the framework. It was the first multilateral disarmament treaty to ban an entire category of weapons of mass destruction. Despite its landmark status, the BWC lacks any formal verification mechanism, a gap that critics and researchers argue has enabled covert biological and neuro-capable weapons development to continue largely unchecked by the international community.
Overview
The BWC prohibits signatory states from developing, producing, stockpiling, or otherwise acquiring or retaining biological agents or toxins of types and in quantities that have no justification for prophylactic, protective, or other peaceful purposes. It likewise bans weapons, equipment, and delivery systems designed to use such agents or toxins for hostile purposes.
Key prohibitions include:
- Development or production of microbial or other biological agents with no peaceful justification
- Stockpiling or acquisition of biological weapons
- Transfer of biological weapons or related technology to any recipient
However, the treaty contains a critical carve-out: research conducted for defensive, protective, or peaceful purposes remains explicitly permitted. This includes studying how pathogens work, developing vaccines and medical countermeasures, and operating biosafety laboratories. In practice, the line between offensive and defensive biological research is extremely thin — the same knowledge, equipment, and agents can serve both purposes. Some researchers note this ambiguity is not accidental, and effectively permits the continuation of offensive-capable programmes under a protective research label.
The BWC does not cover chemical weapons, which are governed separately. The overlap between biological toxins (covered by BWC) and chemical agents (covered by the CWC) creates a contested grey zone, explored further below.
Historical Context
Post-World War II Biological Weapons Programmes
By the end of World War II, multiple nations had developed or actively researched biological weapons. Japan's notorious Unit 731 had conducted biological warfare experiments on prisoners, and the United States, United Kingdom, Canada, and the Soviet Union had all invested in offensive biological programmes.
Operation Paperclip, the covert US programme that absorbed German scientists after the war, had counterpart efforts in the biological sciences, with researchers from Axis biological and chemical weapons units being quietly integrated into US defence research. This provided a foundation of technical knowledge that informed post-war BW programmes on both sides of the Cold War divide.
US Offensive Programme and Nixon's Termination Order
The United States maintained an active offensive biological weapons programme centred at Fort Detrick, Maryland from the 1940s through the late 1960s. In 1969 and 1970, President Richard Nixon issued executive orders unilaterally terminating the US offensive biological and toxin weapons programmes, ordering the destruction of existing stockpiles. This decision set the diplomatic stage for the BWC negotiations that produced the 1972 treaty.
Soviet Biopreparat Violations
In one of the most significant treaty violations of the Cold War, the Soviet Union secretly maintained and vastly expanded its offensive biological weapons programme through a civilian-front organisation called Biopreparat — even after signing and ratifying the BWC. Defectors including Ken Alibek revealed in the 1990s that the USSR had weaponised anthrax, smallpox, plague, and other agents at an industrial scale. The 1979 Sverdlovsk anthrax leak, which killed dozens of Soviet citizens, was officially attributed to contaminated meat but later confirmed as an accidental release from a Biopreparat facility.
This episode demonstrated that the absence of a verification mechanism allowed systematic violation of the BWC to go undetected and unpunished for decades.
Plum Island and Tick-Borne Bioweapons Allegations
One of the most persistent and troubling allegations surrounding covert US biological research concerns the Plum Island Animal Disease Center (PIADC), a government research facility located on a small island off the northeastern tip of Long Island, New York. Originally established in 1954 under the US Department of Agriculture, ostensibly to study foreign animal diseases that might threaten American livestock, Plum Island has been the subject of sustained allegations regarding its dual-use research potential and possible connections to offensive biological weapons work.
The allegations gained significant new credibility through the investigative work of science journalist and researcher Kris Newby, whose 2019 book Bitten: The Secret History of Lyme Disease and Biological Weapons documented her extensive investigation into the origins of Lyme disease and the potential role of weaponised tick research in its emergence. Newby's most startling findings centred on her interviews with Willy Burgdorfer — the Swiss-American entomologist and parasitologist who is credited with discovering the bacterium now named after him, Borrelia burgdorferi, the causative agent of Lyme disease.
According to Newby, Burgdorfer made a series of significant deathbed admissions before his death in 2014. He reportedly told her that during the Cold War he had worked on classified programmes to weaponise ticks and other arthropod vectors — loading them with biological agents capable of causing debilitating illness in human targets. Burgdorfer allegedly confirmed that this work was part of a broader US and NATO biological weapons research effort, and suggested that the explosion of tick-borne illness in the northeastern United States from the 1970s onwards may not have been entirely natural in origin.
Burgdorfer's career intersected directly with the post-war scientific infrastructure assembled under Operation Paperclip. He worked at the Rocky Mountain Laboratories in Hamilton, Montana — a facility with deep connections to US biodefence and, allegedly, offensive biological research — and his expertise in tick biology and spirochete parasitology made him a natural candidate for arthropod-vector weapons programmes.
The allegations, if accurate, carry profound implications for the BWC framework:
- Tick weaponisation research conducted during the Cold War — particularly if it involved deliberate enhancement of pathogen virulence or host-vector engineering — would represent a violation of the spirit of the BWC, and potentially its letter, depending on the timeline relative to the treaty's 1975 entry into force.
- If any such research continued after 1975 under the cover of defensive or veterinary-science justifications at Plum Island, it would constitute a direct breach of BWC obligations.
- The chronic, debilitating, and poorly understood nature of Lyme disease and related tick-borne co-infections — including Bartonella, Babesia, and Anaplasma species — has led some researchers to argue that the clinical profile of these illnesses is more consistent with deliberate engineering than natural pathogen evolution.
It is important to note that these allegations remain disputed and unverified through any official or academic process. The US government has denied that Plum Island was used for offensive weapons research, and mainstream scientific consensus holds that Lyme disease emerged through natural ecological processes. However, the documented history of US biological weapons programmes, the absence of any BWC verification mechanism capable of investigating such claims, and the corroborating details in Burgdorfer's alleged admissions have kept the question open for researchers unwilling to accept official reassurances at face value.
The Plum Island facility was transferred from the Department of Agriculture to the Department of Homeland Security after 2003, and plans to relocate its functions to a new facility — the National Bio and Agro-Defense Facility (NBAF) in Manhattan, Kansas — have been underway for years. Critics have questioned why a facility handling dangerous foreign animal pathogens is being relocated to the continental United States heartland.
.jpg)
For researchers investigating the intersection of covert state programmes and public health, the Plum Island allegations represent a case study in how the BWC's structural weaknesses — particularly its defensive research exemption and its lack of any inspection mechanism — create conditions in which state actors can pursue offensive-capable research with minimal risk of accountability.
Relevance to Neuroweapons
One of the most pressing contemporary questions about the BWC concerns its applicability to neuroweapons — agents and technologies capable of manipulating, incapacitating, or permanently altering human nervous system function.
Neuroweapons may involve:
- Engineered pathogens targeting neural tissue (neurotropic viruses, modified prions)
- Biological toxins with specific neurotoxic profiles (e.g. botulinum toxin, tetrodotoxin, ricin)
- Genetically modified organisms designed to express neuroactive compounds
- Nanotechnological delivery systems — biological vectors used to deliver nanoscale payloads to the central nervous system
The third and fourth categories occupy deeply ambiguous legal territory. If nanotechnological agents — such as those described in research on the Intra-Body Nano Network — are delivered via biological carriers (aerosolised proteins, engineered exosomes, modified viruses), they may technically fall within the BWC's scope. However, since no formal classification has been agreed upon and no verification exists, such agents could be developed and deployed without triggering any enforcement response.
Some researchers and legal scholars argue that the BWC as written is simply not equipped to handle 21st-century convergence technologies that blend biology, chemistry, and nanotechnology. Others suggest the ambiguity is structural and deliberate — allowing state actors to continue developing neurocapable biological agents within the "defensive research" exemption.
The DARPA programme landscape includes multiple projects examining how the nervous system responds to pathogens, toxins, and biological nanoparticles — work that formally qualifies as defensive or medical research, but which accumulates dual-use knowledge with clear offensive implications.
Enforcement Limitations
The BWC's most widely criticised feature is the complete absence of a formal verification mechanism. Unlike the Chemical Weapons Convention, which created the Organisation for the Prohibition of Chemical Weapons (OPCW) with inspection rights and a standing secretariat, the BWC has no equivalent body.
- There is no international inspectorate
- There is no mandatory declaration regime for biological research facilities
- There is no challenge inspection mechanism
- Compliance is essentially self-reported
States parties meet for Review Conferences every five years to assess implementation, and annual Meeting of Experts and Meeting of States Parties sessions take place in the interim, but these are consultative, not enforcement bodies.
The 2001 Verification Protocol Collapse
After seven years of negotiation, an Ad Hoc Group of states parties produced a draft verification protocol in 2001 that would have introduced mandatory declarations, routine facility visits, and challenge inspections. The United States, under the Bush administration, rejected the draft outright at the Fifth Review Conference in July 2001, citing concerns about national security, commercial confidentiality, and the protocol's alleged ineffectiveness.
The rejection effectively killed the verification effort and left the BWC without inspection powers indefinitely. Critics argued — and continue to argue — that this outcome was convenient for states wishing to pursue dual-use biological research without external scrutiny.
Relationship to the Chemical Weapons Convention
The Chemical Weapons Convention (CWC), which entered into force in 1997, governs chemical weapons and created the OPCW as its enforcement body. At face value, the BWC and CWC divide responsibility clearly:
- Biological agents (living organisms, self-replicating systems, biological toxins) → BWC
- Chemical agents (synthetic or extracted non-living toxic chemicals) → CWC
In practice, the border is contested. Mid-spectrum agents — including many biological toxins — are covered by both treaties. Ricin, botulinum toxin, and saxitoxin are explicitly listed as schedule chemicals under the CWC, while also falling under the BWC's toxin provisions.
The emergence of biochemical neuroagents — chemicals derived from or mimicking biological compounds that act on the nervous system — further complicates the picture. Agents engineered to affect mood, cognition, or consciousness may be designed to evade both treaty frameworks simultaneously. See Chemical Weapons Convention for further discussion of the regulatory grey zone.
Implications for Covert Programmes
The defensive research exemption embedded in the BWC has long been identified as a structural loophole enabling the continuation of offensive-capability biological research under legitimate scientific cover.
DARPA has funded research into neurobiological threat assessment, pathogen-host interactions in the nervous system, and bio-inspired nanotechnology — all framed as defensive or medical in purpose, but generating dual-use knowledge directly applicable to offensive neuroweapon development. Dr. James Giordano, a neuroscientist who has lectured extensively to US military and intelligence bodies, has openly discussed how the combination of neuroscience and biotechnology is producing a new generation of weapons that existing legal frameworks — including the BWC — are ill-equipped to address.
The historical precedent of programmes like MK-Ultra — which used both chemical and biological agents in non-consensual human experimentation under the cover of intelligence research — suggests that treaty frameworks provide little barrier when a state actor is sufficiently motivated. The COINTELPRO experience similarly illustrates how domestically focused programmes can run outside legal constraints for years before exposure.
For individuals and researchers investigating targeted individual accounts, the BWC's limitations are directly relevant: if neuro-capable biological agents are being developed or tested outside formal declaration regimes, no international monitoring body currently has the mandate or ability to detect it.
